Research programme: skin disorders therapy - WasatchAlternative Names: Skin disorders therapy research programme - Wasatch
Latest Information Update: 18 Apr 2007
At a glance
- Originator Wasatch Pharmaceutical
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Skin disorders; Wounds
Most Recent Events
- 18 Apr 2007 Discontinued - Clinical-Phase-Unknown for Wounds in USA (unspecified route)
- 18 Apr 2007 Discontinued - Clinical-Phase-Unknown for Skin disorders in USA (unspecified route)
- 07 Aug 2001 New profile